|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with WT mice, HFD- and MCD-fed Smad4<sup>Co/Co</sup> mice showed decreased hepatic steatosis, inflammation, liver cell apoptosis and nonalcoholic fatty liver activity score, reduced plasma glucose, triglyceride, free fatty acids, alanine aminotransferase and aspartate aminotransferase levels but increased adiponectin.
|
29696816 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The lean-with-NAFLD group had significantly higher HOMA-IR (p<0.001) and lower serum adiponectin (p<0.05) than the overweight-without-NAFLD group.
|
29425212 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analaysis of mild NAFPD (MN) and severe NAFPD (SN) subgroups, according to the extent of fat deposition, suggested that NAFLD, triglyceride, lipoprotein, and adiponectin were independent risk factors for NAFPD aggravation (P < .05).The NAFPD prevalence was about 11% in Chinese adults.
|
29953011 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrated that the therapeutic effects of 50% ME among NAFLD rats, were associated with a significant increase in serum adiponectin, reduction in the serum levels of RBP4, vaspin, progranulin, TNF-α, IL-6, and significant downregulation of the hepatic gene expression of PPARγ, SLC10A2, and Collα1.Concomitantly, 50% ME of <i>P. niruri</i> has exhibited a potent antiangiogenic activity on ring assay, cell migration, vascular endothelial growth factor (VEGF), and tube formation, without any cytotoxic effect.
|
30096951 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Measurements included anthropometry, ultrasonography to diagnose NAFLD, fasting glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lipids for adolescents and parents, and additional parameters of blood pressure, body fat percentage (BF%), fasting insulin, apolipoprotein C3, tumour necrosis factor-α and adiponectin for adolescents.
|
30425219 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Participants underwent metabolic and inflammatory profiling (CRP, TNFα, IL-6, IL-8, WISP1, and adiponectin) and magnetic resonance imaging for diagnosing NAFLD on the basis of hepatic fat fraction (≥5.5%) and quantifying visceral and subcutaneous adipose tissue (AT) areas.
|
29471595 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In this study, we aimed to investigate the association between gut microbiota and the DNA methylation of adiponectin (an adipocyte-specific adipocytokine) in rats, following diet-induced NAFLD.
|
30522122 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin and leptin have evolved as crucial signals in many obesity-related pathologies including non-alcoholic fatty liver disease (NAFLD).
|
28758929 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Chinese herb extract improves liver steatosis by promoting the expression of high molecular weight adiponectin in NAFLD rats.
|
28849192 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also examined nine polymorphisms on six non-alcoholic fatty liver disease-related candidate genes (ADIPOQ, APOC3, GCKR, LEPR, PNPLA3, and PPARG).
|
27547913 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
As an integrator of inflammatory pathway networks, nuclear factor-kappa B (NF-κB) regulates expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and anti-inflammatory cytokines, such as adiponectin in NAFLD.
|
29037210 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum adiponectin concentrations were decreased in both NAFLD groups compared to controls (P<0.001 for both groups) The metabolomics study revealed a potential role for various lysophosphatidylcholines (lyso-PC C18:0, lyso-PC C17:0) and phosphatidylcholines (PCaa C36:3; false discovery rate (FDR)-corrected P-value<0.001) as well as lysine, tyrosine, and valine (FDR<0.001).
|
27527746 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Caffeoylquinic Acid-Rich Extract of <i>Aster glehni</i> F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPAR<i>δ</i> and Adiponectin in ApoE KO Mice.
|
29201040 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BMI-Z score, HOMA IR, serum adiponectin and HDL levels were not associated with NAFL, however TG were significantly associated(OR = 3.22 (95% CI: 1.01-10.25, p = 0.04)).
|
28446162 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the T45G polymorphism of the adiponectin gene may not constitute an NAFLD risk factor.
|
26909902 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTX-3 and hsCRP levels were higher and adiponectin levels were lower in the NAFLD group compared to the healthy controls (p < 0.001 for all).
|
27831642 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was also a significant association between the G variant of AdipoQ rs1501299 G>T polymorphism and an increased risk of NAFLD.
|
25385252 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We suggest that the regular supplementation of soybean embryos might be a useful treatment for preventing NAFLD and associated complications through upregulation of adiponectin-mediated AMPKα pathway parameters, which are implicated in antioxidant, anti-inflammatory, and lipid metabolism activities.
|
27266339 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of adiponectin gene polymorphisms and additional gene-gene interaction with nonalcoholic fatty liver disease in the Chinese Han population.
|
26865047 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of TNF-α, endotoxins, and insulin were significantly higher and of adiponectin lower in NAFLD in comparison with CVH and healthy volunteers.
|
26212089 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The gene polymorphisms of adiponectin-encoding gene (ADIPOQ), leptin receptor (LEPR), apolipoprotein C3 (APOC3), peroxisome proliferator-activated receptors (PPAR), sterol regulatory elementbinding proteins (SREBP), transmembrane 6 superfamily member 2 (TM6SF2), microsomal triglyceride transfer protein (MTTP), tumor necrosis factors-alpha (TNF-α) and manganese superoxide dismutase (MnSOD) have been reported to be related to NAFLD and CAD.
|
26965314 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The risk of NAFLD significantly increased in patients with adiponectin gene promoter-11377C/G (CG) genotype [odds ratio (OR)NAFL = 2.5278; ORNASH = 6.1823; ORNAFHC = 17.8570), in those with -11377C/G (GG) genotype (ORNAFL = 2.5900; ORNASH = 6.4017; ORNAFHC = 18.9023), in those with GPx-1 gene C594T (CT) genotype (ORNAFL = 2.6687; ORNASH = 6.7772; ORNAFHC = 22.2063), and in those with C594T (TT) genotype (ORNAFL = 2.6330; ORNASH = 6.4729; ORNAFHC = 21.5682).
|
26897098 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Body fat and serum HMW adiponectin levels were the strongest predictors of developing NAFLD (p < 0.001 and 0.004, respectively).
|
26042596 |
2015 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The tagSNPs rs2241767, rs1501299 and rs3774261 in the adiponectin gene are risk factors for the individuals' susceptibility to and progression of NAFLD.
|
26334200 |
2015 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ADPN I148M polymorphism has been consistently reported to play a role in liver-associated diseases, such as alcoholic liver disease, chronic hepatitis C, and liver fat and fibrosis in nonalcoholic fatty liver disease.
|
26632699 |
2015 |